Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

ARIAD Presents Data for Investigational Inhibitor

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
New preclinical data showing AP26113 inhibits clinically relevant mutants of ALK and ROS1.

ARIAD Pharmaceuticals, Inc. announced the presentation of preclinical data on AP26113, an investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), and c-ros oncogene 1 (ROS1), at the American Association for Cancer Research (AACR) Annual Meeting 2013, in Washington.

The study, “AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions,” shows that AP26113 inhibits clinically relevant crizotinib-resistant ALK mutants and oncogenic ROS1 fusions recently identified in patients with non-small cell lung cancer (NSCLC).

The research conducted by ARIAD scientists was determined using cell lines harboring crizotinib-resistant mutant forms of ALK and oncogenic ROS1 fusions, tested in both in vitro studies and mouse-disease models.

“This preclinical research demonstrates that AP26113 inhibits all nine clinically identified crizotinib-resistant ALK mutations, at plasma concentrations we know to be clinically achievable,” said Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. “Some of these mutations were also shown to be resistant to additional ALK inhibitors other than crizotinib. This supports the potential of AP26113 to offer a pan-ALK inhibitor profile.”

AP26113 was also shown to inhibit ROS1 fusions as potently as it inhibits ALK, to retain activity against the gatekeeper mutation of ROS1, and to substantially suppress the outgrowth of resistant ROS1 cells in a mutation assay, all at clinically achievable plasma concentrations. These data suggest that AP26113 may be able to avoid the emergence of drug-resistant mutants in NSCLC patients with these oncogenic gene fusions.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ARIAD Announces Appointments of Key Members of Leadership Team
Ready for anticipated regulatory approval and launch of Iclusig® in Europe this year.
Friday, February 22, 2013
ARIAD’s AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor
Paper Features Design and Preclinical Characterization of AP24534; Data demonstrate inhibition of all known variants of the CML target protein.
Tuesday, November 03, 2009
ARIAD Announces Preliminary Results from Ongoing Clinical Trial of its Investigational Bcr-Abl Inhibitor
The study provides initial clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534 in heavily pretreated CML patients.
Tuesday, July 28, 2009
ARIAD Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients with Advanced Endometrial Cancer
Deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies.
Thursday, August 07, 2008
ARIAD Announces Start of Phase 2 Clinical Trial of Oral Deforolimus in Breast Cancer Patients
ARIAD will receive a $15 million milestone payment from Merck for treating the first patient in the breast cancer clinical trial.
Tuesday, August 05, 2008
New Study by ARIAD Scientists Offers Insights into Design of Small-Molecule Drugs to Treat Drug-Resistant Leukemia
ARIAD publishes the high-resolution structure of the protein responsible for a major clinically relevant genetic variant of drug-resistant chronic myeloid leukemia.
Wednesday, October 10, 2007
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Gene Therapy Going Global with Portable Device
Portable 'gene therapy in a box' could make future cancer and HIV cures affordable in developing countries.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
3D-Printed Heart-On-A-Chip with Integrated Sensors
Researchers have created the first 3D-printed organ-on-a-chip with integrated sensors, paving the way for more complex, customizable devices.
Wrapping up the Genome
Researchers successfully package complete yeast genome using purified components, yielding new insights into genome mechanisms.
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.
Precision Medicine Guiding Cancer Patients’ Chemotherapy Decision
New study finds doctors use genetic test to measure breast cancer recurrence risk, make tailored treatment recommendations.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos